News Room

Topics
Regions
Year of publication

All News

 News
Amrita Hospital Joins the SOPHiA GENETICS Community

Exciting news! We are thrilled to welcome Amrita Hospital to our network. Based in Faridabad, India, Amrita Hospital is recognized as one of the premier healthcare institutions. The hospital improves the well-being of the local community through initiatives aimed at providing outstanding and affordable medical care in the spirit of compassion to all.   The hospital […]

M42, AstraZeneca & SOPHiA GENETICS Launch UAE Liquid Biopsy Initiative to Transform Cancer Care

Abu Dhabi, United Arab Emirates; June 3, 2025: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and […]

Bioma Genetics Expands Partnership with SOPHiA GENETICS

We’re proud to announce that Bioma Genetics, a leading precision medicine center in Brazil, has expanded its partnership with SOPHiA GENETICS by adopting the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. This advanced application enables the accurate identification of HRR gene mutations and genomic instability, providing researchers with comprehensive insights into HRD status. By integrating this […]

SOPHiA GENETICS Reports First Quarter 2025 Results

BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount […]

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

BOSTON, MA and ROLLE, Switzerland, April 28, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October […]

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call […]

SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC

BOSTON, MA, and ROLLE, Switzerland, March 18, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for […]

SOPHiA GENETICS To Present at the NVIDIA GTC AI Conference

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that CEO and Co-founder Dr. Jurgi Camblong will present at the NVIDIA GTC in San Jose, California on March 17, 2025 at 101:00 a.m. PDT. The session titled “Interpret Health Data With AI to Change the Future of […]

 News

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview
Unlocking Insights, Transforming Healthcare
Learn About SOPHiA DDM™ 
SOPHiA DDM™ for Genomics

Oncology 

Rare and Inherited Disorders

Add-On Modules

SOPHiA DDM™ for Radiomics
Unlock entirely novel insights from your radiology images
Learn About SOPHiA DDM™ for Radiomics 
SOPHiA DDM™ for Multimodal
Explore new frontiers in biology and disease through novel insights
Learn About SOPHiA DDM™ for Multimodal
Professional Services
Accelerate breakthroughs with our tailored enablement services
Learn About our Professional Services